KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.54
+0.63 (3.96%)
At close: Jan 22, 2026, 4:00 PM EST
16.54
0.00 (0.00%)
After-hours: Jan 22, 2026, 4:38 PM EST
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
$5,281
Profits / Employee
-$752,211
Market Cap
836.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Apr 30, 2025 | 270 | 120 | 80.00% |
| Apr 30, 2024 | 150 | 32 | 27.12% |
| Apr 30, 2023 | 118 | 13 | 12.38% |
| Apr 30, 2022 | 105 | 35 | 50.00% |
| Apr 30, 2021 | 70 | 14 | 25.00% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Arvinas | 430 |
| REGENXBIO | 353 |
| Prime Medicine | 214 |
| Omeros | 202 |
| Kura Oncology | 192 |
| Arbutus Biopharma | 44 |
| Jade Biosciences | 30 |
KALV News
- 13 days ago - KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
- 14 days ago - KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 2 months ago - KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Business Wire
- 2 months ago - KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting - Business Wire
- 2 months ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire